

## Fluidigm to Announce Q2 2016 Financial Results and Host Conference Call for Investors

SOUTH SAN FRANCISCO, Calif., July 28, 2016 — Fluidigm Corporation (NASDAQ:FLDM) today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016, after the financial markets close.

Gajus Worthington, Fluidigm president and chief executive officer, and Vikram Jog, chief financial officer, will host a conference call at 2:00 p.m. PT (5:00 p.m. ET) on August 4, 2016, to discuss second quarter 2016 financial results and 2016 outlook. A press release outlining the financial results will be publicly distributed prior to the call.

Individuals interested in listening to the conference call may do so by dialing (877) 556-5248 for domestic callers, or (720) 545-0029 for international callers. Please reference Conference ID 34161018. Interested parties may access the live teleconference in the Investor Relations section of the company's website at: <a href="http://investors.fluidigm.com/events.cfm">http://investors.fluidigm.com/events.cfm</a>. The link will not be active until 1:45 p.m. PT (4:45 p.m. ET) on August 4, 2016.

A telephone replay of the teleconference will be available 90 minutes after the end of the call at (855) 859-2056 (domestic toll-free), or (404) 537-3406 (international toll), Conference ID 34161018. The conference call will also be archived on the Fluidigm Investors page at: <a href="http://investors.fluidigm.com/">http://investors.fluidigm.com/</a>.

## **Use of Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to expected market opportunities and the potential of Fluidigm's President and Chief Operating Officer to drive growth, innovation, and customer delight. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the potential for delays in the timing of new product releases; the potential for product performance or quality issues in new products and risks associated with Fluidigm's ability to address such issues; intellectual property risks; competition; Fluidigm's research and development, sales, marketing, and distribution plans and capabilities; reduction in research and development spending or changes in budget priorities by customers; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Fluidigm's business and operating results are contained in Fluidigm's Annual Report on Form 10-K for the year ended December 31, 2015, and in its other filings with the Securities and Exchange Commission. Additional information will also be set forth in Fluidigm's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 to be filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements except as may be required by law.

## **About Fluidigm**

Fluidigm (NASDAQ:FLDM) develops, manufactures and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories and pharmaceutical, biotechnology and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

We use our website (<a href="www.fluidigm.com">www.fluidigm.com</a>), corporate Twitter account (<a href="@fluidigm">@fluidigm</a>), Facebook page (<a href="https://www.facebook.com/Fluidigm">https://www.facebook.com/Fluidigm</a>) and LinkedIn page (<a href="https://www.linkedin.com/company/fluidigm-corporation">https://www.linkedin.com/company/fluidigm-corporation</a>) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls and webcasts.

Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.

## Contact

Fluidigm Corporation

Ana Petrovic
Director, Corporate Development and Investor Relations
650.243.6628 (Office)
ana.petrovic@fluidigm.com